Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Cellular Therapy For Pulmonary Tuberculosis

Specialists of the Central Scientific Research Institute of Tuberculosis (Russian Academy of Medical Sciences) and the Medical Radiological Research Center (Russian Academy of Medical Sciences) have been developing for three years a treatment mode for pulmonary tuberculosis stable forms.

The mode, on top of traditional complex therapy, includes stem cells intravenous injection to the patient, the stem cells being educed from his/her own marrow (mesenchymal stem cells). Clinical observations have proved that in such a way tubercular process can be stopped with practically incurable patients and their state of health can be improved significantly.

The researchers are studing twenty seven patients with stable forms of pulmonary tuberculosis. Pathogenes of these forms are resistant to the majority of antituberculous drugs, including the most active ones. In essence, these patients feel as the people ill with consumption did in the 19th century. Their lungs gradually decay, and the patients pose constant danger to people around as they excrete mycobacteria - tuberculosis pathogenes. Marrow (mesenchymal) stem cells can restore injured pulmonary tissues and increase patients’ resistivity to infection. They possess the property of differentiating into the cells of bone stock, cartilaginous tissue, adipose tissue and some other tissues – including the cells of healthy respiratory epithelium.

To get the stem cells, the patient underwent sternal puncture or iliac bone puncture. The obtained marrow cells were cultivated, (mesenchymal) stem cells being educed and reproduced in the course of cultivation. Transplantation required 150-200 million cells that were injected intravenously to the patient. In the majority of cases, the procedure did not cause complications, and annoying sensations (moderate temperature, ache, a worn out feeling), if any, were over on the next day. The researchers observed 16 patients for 18 to 24 months, and 11 patients – for at least six months. Within the first five months, all patients felt better: dyspnea reduced, asthenia and indisposition were almost over. Twenty four patients gained weight significantly and noted revitalization and burst of energy. Patients’ indicies of blood noticeably improved.

Three to four months after the transplantation, twenty patients ceased to excrete mycobacteria, this meaning that the active process in the lungs had stopped. According to the tomographic imaging research data, chronic cavities in the pulmonary tissue healed up with 11 patients; cavities in both lungs (that had existed for two years) closed with one of the patients. Inflammatory changes in the lungs dissolved with 15 patients, the lysis cavities partly closed or decreased in size.

At present, 9 patients out of 16, who were injected stem cells 18 to 24 month ago, demonstrate steady remission of tubercular process, the inflammatory changes dissolving and destructive changes disappearing in the lungs, the researchers observed considerable positive dynamics with 6 patients. Only in one case out of 16, the mesenchymal stem cells transplantation effect resulted only in a short-term improvement. The patients who underwent cells transplantation several months ago, continue their treatment, the efficiency of which may be judged 12 to 15 months later.

Although mechanisms of stem cells action are not quite clear yet, the results are promising and they allow to count on new prospects in treatment of stable forms of tuberculosis.

Nadezda Markina | alfa
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

A new kind of quantum bits in two dimensions

19.03.2018 | Physics and Astronomy

Scientists have a new way to gauge the growth of nanowires

19.03.2018 | Materials Sciences

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Science & Research
Overview of more VideoLinks >>>